Augenheilkunde up2date, Table of Contents Augenheilkunde up2date 2014; 4(2): 105-116DOI: 10.1055/s-0033-1357923 Grundlagen Georg Thieme Verlag KG Stuttgart · New York Therapie von Blutungen bei Patienten unter oraler Antikoagulation[1] Treatment of Bleeding in Patients Undergoing Oral Anticoagulant Therapy Hanno Riess Charité, Medizinische Klinik Campus Virchow-Klinikum, Berlin › Author Affiliations Recommend Article Abstract Buy Article All articles of this category Sowohl unter einer Therapie mit klassischen Antikoagulanzien wie auch unter den direkten oralen Antikoagulanzien sind Blutungen die wichtigste klinische Komplikation. Deren Therapie unterscheidet sich zwischen den Substanzgruppen erheblich. Full Text References Literatur 1 Heit JA. The Epidemiology of Venous Thromboembolism in the Community. Arterioscler Thromb Vasc Biol 2008; 28: 370-372 2 Lakshminarayan K, Anderson DC, Herzog CA et al. Clinical epidemiology of atrial fibrillation and related cerebrovascular events in the United States. Neurologist 2008; 14: 143-150 3 Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 2011; 31: 326-343 4 Pengo V, Pegoraro C, Cucchini U et al. Worldwide management of oral anticoagulant therapy: the ISAM study. J Thromb Thrombolysis 2006; 21: 73-77 5 Kimmel SE. Warfarin therapy: in need of improvement after all these years. Expert Opin Pharmacother 2008; 9: 677-686 6 Palareti G. Bleeding with anticoagulant treatments. Hämostaseologie 2011; 31: 237-242 7 Lubetsky A, Yonath H, Olchovsky D et al. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med 2003; 163: 2469-2473 8 Leissinger CA, Blatt PM, Hoots WK et al. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol 2008; 83: 137-143 9 Makris M, van Veen JJ, Maclean R. Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient. J Thromb Thrombolysis 2010; 29: 171-181 10 Goldstein JN, Thomas SH, Frontiero V et al. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke 2006; 37: 151-155 11 Pradaxa, summary of product characteristics. Im Internet:. http://www.pradaxa.com Stand: August 2012 12 Eikelboom JW, Wallentin L, Connolly SJ et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363-2372 13 Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352 14 Van Ryn J, Stangier J, Haertter S et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127 15 Douxfils J, Mullier F, Robert S et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Thromb Haemost 2012; 107: 985-997 16 Freyburger G, Macouillard G, Labrouche S et al. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 2011; 127: 457-465 17 Xarelto, summary of product characteristics. Im Internet:. http://www.xarelto.com/en/information-on-xarelto/summary-of-product-characteristics Stand: August 2012 18 Eliquis, summary of product characteristics. Im Internet:. http://www.eliquis.eu/eliquis_smpc.aspx Stand: August 2012 19 Samama MM, Martinoli JL, LeFlem L et al. Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor. Thromb Haemost 2010; 103: 815-825 20 Harder S. Renal Profiles of Anticoagulants. J Clin Pharmacol 2012; 52: 964-975 21 Zhou W, Schwarting S, Illanes S et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011; 42: 3594-3599 22 Eerenberg ES, Kamphuisen PW, Sijpkens MK et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579 23 Gruber A, Marzec UM, Buetehorn U et al. Potential of activated prothrombin complex concentrate and activated factor VII to reverse the anticoagulant effects of rivaroxaban in primates. Blood 2008; 112: 3825 24 Godier A, Miclot A, Le Bonniec B et al. Evaluation of Prothrombin Complex Concentrate and Recombinant Activated Factor VII to Reverse Rivaroxaban in a Rabbit Model. Anesthesiology 2012; 116: 94-102 25 Warkentin TE, Margetts P, Connolly SJ et al. Recombinant factor VII a (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 2012; 119: 2172-2174 26 Crowther MA, Warkentin TE. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood 2008; 111: 4871-4879 27 Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151 28 Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891 29 Granger CB, Alexander JH, McMurray JJV et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2011; 365: 981-992 30 Moser M, Bode C. Anticoagulation in atrial fibrillation – A new era has begun. Hamostaseologie 2012; 32: 37-39
